Actions
Pages
Subscribe for newsletter
Stories
Sanofi (Nasdaq: $SNY), a multinational pharmaceutical and healthcare company, in a strategic move towards becoming a frontrunner in AI-powered drug discovery, invests $10 million in California-based BioMap. This collaboration aims to leverage BioMap's cutting-edge AI engine, turning data sets into a biological map of proteins, advancing drug discovery across immunology, neurology, oncology, and rare diseases.
The partnership highlights the convergence of Biotech and Tech and validates that AI has important industry applications beyond consumer tech. Sanofi's commitment to being the first pharmaceutical company powered by AI at scale gains momentum with this collaboration. The partnership with BioMap aligns with Sanofi's broader strategy to harness AI and data science capabilities, optimizing the discovery and development of groundbreaking biotherapeutics.
"By combining Sanofi’s proprietary data sets, digital infrastructure, AI, and data science capabilities with BioMap’s AI engine, we can optimize the process of discovery and development of breakthrough biotherapeutics." - Matt Truppo, Sanofi’s Global Head of Research Platforms.
The collaboration marks a significant step towards Sanofi's ambition to lead in AI-driven pharmaceuticals. The partnership sets the stage for transformative advancements in drug discovery, hinting at a future where AI plays a pivotal role in optimizing treatment development.
In the broader landscape of AI-driven advancements, Sanofi's strategic collaborations with Exscientia, Atomwise, Insilico, and Owkin form a cohesive tapestry, positioning the pharmaceutical giant at the forefront of AI innovation. Committing over $2 billion total to these companies, this multifaceted approach is integral to Sanofi's vision of becoming the inaugural pharmaceutical company powered by artificial intelligence at scale.
In the broader context of AI's transformative influence on the landscape of pharmaceuticals, Google DeepMind's Alphafold stands as a groundbreaking example. Recently acclaimed for predicting protein structures with remarkable accuracy, Alphafold exemplifies the prowess of AI methodologies in understanding complex biological systems.
As Sanofi assembles an extensive AI toolkit through collaborations, DeepMind's success with Alphafold serves as a testament to the potential of AI in unraveling intricate biological processes. This synergy between Sanofi's collaborations and breakthroughs like Alphafold heralds a new era where AI is not just a tool but a transformative force in the sector.
Pharmaceuticals, AI-driven Drug Discovery
Story
Genesis Therapeutics harnesses AI in a landmark $200 million funding round, highlighting a pivotal moment for AI-enabled drug development and the biotech sector's rapid growth.
The substantial investment in Genesis underscores a broader confidence in AI's role in pioneering advanced drug discovery and development, signaling a potential shift in traditional biotech strategies. This evolution is not just theoretical; it's now entering a practical, critical stage with real-world impacts.
"AI presents a potent opportunity to revolutionize the drug discovery process," said CEO Dr. Evan Feinberg. "This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic."
The industry anticipates the forthcoming clinical trials of Genesis' AI-enabled drug candidates, marking a significant milestone in AI's practical application in biotech. Success here could catalyze a larger shift toward technology-driven approaches in the sector.
This development is part of a larger trend. Companies like Mana.bio are also merging AI with biotech for drug development, emphasizing the growing importance of technology in this field. Despite external challenges, such as recent attacks in Israel impacting Mana.bio’s operations, these companies remain steadfast in their missions, showing the resilience and urgency of innovation in this space.
Biotech & Artificial Intelligence
Story
While lithium-ion batteries have made impressive strides, a tech startup believes there's untapped potential in existing designs. Breathe Battery Technologies is breathing new life into lithium-ion batteries with cutting-edge software that promises faster charging times and enhanced longevity.
Lithium-ion batteries have become the lifeblood of the rapidly growing electric vehicle (EV) market, constituting 60% of the world's battery production, with no signs of slowing down. Breathe's innovation can reshape the EV landscape by making batteries more efficient and sustainable.
Ian Campbell, Co-founder and CEO at Breathe, states, "Customers get a better, longer-lasting laptop or car. If you're the OEM that sells it to us, you have a more sustainable product, you have better warrantability, you have less balance sheet risk."
The automotive sector is set to be the focal point of Breathe's endeavors. With electric vehicles on the rise, lithium-ion batteries are in high demand. Breathe's software promises to further transform the EV market by making these vehicles more efficient, sustainable, and cost-effective. Conversations with car manufacturers are already in advanced stages, with tremendous excitement in the automotive industry.
Breathe's software operates on industry-standard microcontrollers, ensuring broad compatibility in electric vehicles and electronic devices. This innovation aligns with the global trend toward more sustainable transportation solutions and cleaner energy practices.
Emerging Technology in Battery Optimization
Breathe Battery Technologies' pioneering software is set to redefine the lithium-ion battery industry, offering a brighter and more sustainable future for electronic devices and electric vehicles alike. As the automotive sector continues to expand, Breathe's innovations are poised to play a pivotal role in shaping the industry's future.
Story
Innovators
Scroll
Open
Close